OVERVIEW: What every practitioner needs to know
Treacher-Collins syndrome (TCS, also known as mandibulofacial dysostosis or Franceschetti-Zwahlen-Klein syndrome) is an autosomal dominant condition that typically results from a spontaneous mutation in the gene TCOF1, which encodes a nucleolar phosphoprotein named Treacle. TCS results in symmetric craniofacial defects, the severity of which varies considerably from person to person and generation to generation. Deformities in TCS are confined to the head and neck. No correlation exists between genotype and phenotype. Patients with TCS generally show normal intelligence but frequently have conductive hearing loss. Therefore, providers should identify and correct any underlying hearing problems to maximize the development of these patients. Initial treatment is aimed at ensuring that the airway is secure.
Are you sure your patient has TCS? What are the typical findings for this disease?
TCS generally results in the following symmetric craniofacial deformities:
Lateral downward sloping palpebral fissures (89%)
Zygomatic hypoplasia (81%)
Mandibular hypoplasia (78%)Related Content
External ear abnormalities (77%)
Absence of lid lashes medial to defect (69%)
External auditory canal atresia (36%)
Cleft palate (28%)
Genetic analysis identifies mutations in the TCOF1 gene in 90% of patients. Over 130 different mutations have been identified in the TCOF1 gene, requiring full gene sequencing to make the diagnosis.
What other disease/condition shares some of these symptoms?
Other conditions with craniofacial defects:
Pierre Robin Sequence
Stickler and Marshall Syndromes
Van Der Woude Syndrome
What caused this disease to develop at this time?
TCS is present at birth due to failure of the 1st and 2nd branchial arches to develop properly in utero. Greater than 90% of cases of TCS are the result of an autosomal dominant mutation on the TCOF1 gene, which encodes the protein Treacle, and which has been shown to be critical in ribosome biogenesis. Given the autosomal dominant inheritance pattern, children of affected individuals have a 50% probability of inheriting the mutation; however, the majority (60%) of patients with TCS have de novo gene mutations.
What laboratory studies should you request to help confirm the diagnosis? How should you interpret the results?
Historically, TCS was a clinical diagnosis. Now, genetic analysis of the gene TCOF1 will detect mutations in 90% of patients; thus, the presence of appropriate deformities with a mutation in TCOF1 is sufficient for a diagnosis of TCS.
Between 7%-20% of patients will have no mutations identified in TCOF1 despite a classic TCS phenotype. In these patients, a TCS diagnosis can be made if other craniofacial syndromes are excluded. Research published in 2011 identified the presence of mutations in other ribosomal related genes (POLR1C & POLR1D) in TCS patients without identifiable mutations in TCOF1.
Would imaging studies be helpful? If so, which ones?
Temporal bone CT – assesses for irregular or absent auditory ossicles or complete absence of the middle ear and epitympanic space.
Conventional head/facial CT – detects hypoplastic or absent zygomatic arches, choanal shortening, a small mandible with retrognathism, and narrowing of the maxilla.
Occipitomental radiographs – detect hypoplasia of the zygomatic arch (less frequently performed now that computed tomography (CT) scans are commonly performed).
Confirming the diagnosis
Trainor et al. put forth a diagnostic algorithm (Figure 1). In their algorithm, confirmation of TCS by mutational analysis of TCOF1 requires management by a comprehensive team consisting of a craniofacial surgeon, orthodontist, ophthalmologist, otolaryngologist, and speech pathologist. Absence of a TCOF1 mutation prompts a search for an alternative diagnosis (i.e., Nager Syndrome);
Use caution, as a subset of patients with phenotypic TCS (7%-20%) will have no mutations identified in TCOF1.
If you are able to confirm that the patient has TCS, what treatment should be initiated?
A multidisciplinary approach towards patients with TCS is required and should include craniofacial surgeons, otolaryngologists, orthodontists, ophthalmologists, speech pathologists, and geneticists.
Immediate: Initial management should emphasis the airway, as patients with severe micrognathia and subsequent obstruction of the hypopharynx may require tracheostomy or measures such as long-term placement of a nasopharyngeal airway to secure their airway.
Eyelid coloboma surgical repair (age ~1-3 years)
Cleft palate repair (age ~1-3 years)
Orbital reconstruction (age 5-7 years)
Mandibular distraction or maxillo-mandibular osteotomies (age 5-7 years)
May consider earlier if sleep apnea is a major issue and the child does not have a tracheostomy tube placed.
External/internal ear reconstruction (age 6 years)
What are the possible outcomes of TCS?
While the majority of new cases of TCS are caused by spontaneous mutations in TCOF1, patients with TCS have a 50% chance of having children with TCS. Patients should be counseled that the severity of the disease has dramatic variability between generations and siblings.
Because of the high degree of phenotypic variation, there are case reports of parents with subtle deformities being diagnosed with TCS only after having children who present with more severe deformities. Parents of a child affected with TCS should have an evaluation and genetic counseling for TCS, especially if they are considering have additional children.
Typically, patients will require multiple surgeries and never attain “normal” cosmesis. In a study of 50 patients with TCS, the average patient underwent 5.2 operations.
What causes this disease and how frequent is it?
Worldwide incidence: 1 in 25,000 – 50,000 live births
60% of cases occur spontaneously
Located on chromosome 5 (5q31.3-q33.3)
Encodes the nucleolar phosphoprotein, Treacle, which is highly expressed in neural crest cells of the brachial arches
Treacle is essential in ribosomal RNA transcription and ribosome biogenesis.
90% of patients have a mutation in the gene TCOF1
>130 mutations in TCOF1 have been identified
Defects have variable penetrance. No correlation between specific mutations and clinical severity has been established.
Located on chromosome 13
Encodes subunit of RNA polymerase I and III
~8% of patients negative for TCOF1 have mutations in POLR1D
Supports hypothesis that TCS is a ribosomopathy
How do these pathogens/genes/exposures cause the disease?
Currently, there is no evidence that pathogens or exposures
in utero can cause TCS. While ongoing studies are elucidating the mechanisms by which TCS causes deformities, it is generally agreed that TCS is the result of an abnormality of the neuroepithelium of the first and second branchial arches. Previously, the phenotype was thought to be a consequence of decreased neural crest cell migration; however, new studies implicate increased apoptosis and decreased proliferation of neuroepithelial cells.
TCOF1 gene mutations were thought to be necessary to develop TCS, but a recent subset of patients who phenotypically have TCS without a TCOF1 mutation have been identified. Eight percent of these patients were found to have mutations in POLR1C or POLR1D.
Other clinical manifestations that might help with diagnosis and management
Prenatal diagnosis with amniocentesis, chorionic villus sampling or ultrasound are possible to detect mutations in TCOF1. Due to the high degree of variability of the TCS phenotype, decisions regarding testing and management are difficult and should be discussed with a geneticist.
Other clinical considerations for airway management
While watchful waiting is an appropriate option for the initial airway management in a newborn with TCS and mild airway compromise, frequently additional interventions are required because of frank respiratory distress, failure to thrive, or obstructive sleep apnea (OSA). Evaluation of airway compromise can involve the use of polysomnography and feeding evaluation. Management options include:
Long-term nasopharyngeal airway – While studies are limited in the use of long-term nasopharnygeal airway (NPA) in TCS, in a study of patients with syndromic craniosynostosis, NPA was preferred by parents over tracheostomy and reduced, but did not always completely ameliorate, the severity of OSA.
Tracheostomy – In one series, ~40% of TCS patients eventually underwent tracheostomy. While tracheostomy can definitively alleviate upper airway obstructions, it is associated with increased rates of tracheal stenosis, granulomas, and other complications.
Distraction osteogenesis (DO) – Involves making a cut in the maxilla or mandible or both, and applying tension to separate the bone, thus allowing new bone formation in between the cut ends. DO is indicated for infants and children with OSA secondary to micrognathia or midface hypoplasia.
Other management strategies, including positive airway pressure and oxygen therapy, as discussed in the OSA section.
Respiratory compromise in TCS is not limited to the neonatal period. OSA is present in the majority of pediatric and adult TCS patients with no correlation between the severity of TCS and the severity of OSA. While there is no consensus on the timing and frequency for polysomnography, given the morbidity and mortality associated with OSA and the high prevalence of OSA in TCS patients, screening for OSA should be considered early.
How can TCS be prevented?
While TCS is an autosomal dominant disease, the majority of patients with TCS have mutations that occur spontaneously. Patients who might wish to have children should be referred for genetic counseling, because they have a 50% chance of passing on this condition to their offspring.
There is no current method for preventing new mutations. Mouse models have validated the role of pharmacologic and genetic inhibition of tumor suppressor p53 to prevent TCS; however, this is not currently a viable preventative strategy because the insult occurs early in embryological development, and perturbation with p53 results in tumor formation.
What is the evidence?
Dauwerse, JG, Dixon, J, Seland, S. “Mutations in genes encoding subunits of RNA polymerases I and III cause Treacher Collins syndrome”. Nat Genet. vol. 43. 2011. pp. 20-2. (This paper is important in the TCS literature because it describes a series of patients that have TCS but do not have mutations in TCOF1.)
Trainor, PA, Dixon, J, Dixon, MJ. “Treacher Collins syndrome: etiology, pathogenesis and prevention”. Eur J Hum Genet. vol. 17. 2009. pp. 275-83. (This relatively recent review provides a comprehensive background and overview of TCS.)
Donnai, D, Hughes, HE, Winter, RM. “Postaxial acrofacial dysostosis (Miller) syndrome”. J Med Genet. vol. 24. 1987. pp. 422-5. (A good review of one of the other syndromes that is on the initial differential for a TCS patient)
Shanske, AL, Bogdanow, A, Shprintzen, RJ, Marion, RW. “The Marshall syndrome: report of a new family and review of the literature”. Am J Med Genet. vol. 70. 1997. pp. 52-7. (A good review of one of the other syndromes that is on the initial differential for a TCS patient)
Rizos, M, Spyropoulos, MN. “Van der Woude syndrome: a review. Cardinal signs, epidemiology, associated features, differential diagnosis, expressivity, genetic counselling and treatment”. Eur J Orthod. vol. 26. 2004. pp. 17-24. (A good review of one of the other syndromes that is on the initial differential for a TCS patient)
Teber, OA, Gillessen-Kaesbach, G, Fischer, S. “Genotyping in 46 patients with tentative diagnosis of Treacher Collins syndrome revealed unexpected phenotypic variation”. Eur J Hum Genet. vol. 12. 2004. pp. 879-90. (This article describes a myriad of mutations that can be identified in a TCS cohort.)
Kobus, K, Wójcicki, P. “Surgical treatment of Treacher Collins syndrome”. Ann Plast Surg. vol. 56. 2006. pp. 549-54. (This paper describes one hospital's surgical experience with 55 TCS patients whose ages ranged from 1-32 years old.)
Poswillo, D. “The pathogenesis of the Treacher Collins syndrome (mandibulofacial dysostosis)”. Br J Oral Surg. vol. 13. 1975. pp. 1-26. (This paper provides historical context for the study of the mechanism of action of TCS.)
Dixon, J, Jones, NC, Sandell, LL. “Tcof1/Treacle is required for neural crest cell formation and proliferation deficiencies that cause craniofacial abnormalities”. Proc Natl Acad Sci U S A. vol. 103. 2006. pp. 13403-8. (Using a mouse model, this paper demonstrates that loss of TCOF1 results in decreased neural crest cell migration.)
Katsanis, SH, Jabs, EW, Pagon, RA, Bird, TD, Dolan, DR. “Treacher Collins syndrome”. GeneReviews [Internet]. 2004. (This is an updated review of TCS diagnosis, testing, and management.)
Randhawa, PS, Ahmed, J, Nouraei, SR, Wyatt, ME. “Impact of long-term nasopharyngeal airway on health-related quality of life of chlidren with obstructive sleep apnea caused by syndromic craniosynostosis”. J Craniofac Surg. vol. 22. 2011. pp. 125-8. (While there are no studies looking at the use of a nasopharyngeal airway (NPA) for obstructive sleep apnea (OSA) on patients with TCS, this article does demonstrate that the NPAs can help reduce the severity of OSA for patients with other craniofacial syndromes.)
Sculerati, N, Gottlieb, MD, Zimbler, MS. “Airway management in children with major craniofacial anomalies”. Laryngoscope. vol. 108. 1998. pp. 1806-12. (This paper looks at a group of children with craniofacial deformities and determines the rates of surgical airway management and factors affecting decannulation.)
Bouchard, C, Troulis, MJ, Kaban, LB. “Management of obstructive sleep apnea: role of distraction osteogenesis”. Oral Maxillofac Surg Clin North Am. vol. 21. 2009. pp. 459-75. (This article discusses the use of distraction osteogenesis for treatment of obstructive sleep apnea, and specifically addresses its use for patients with craniofacial deformities.)
Akre, H, Øverland, B, Åsten, P. “Obstructive sleep apnea in Treacher Collins syndrome”. Eur Arch Otorhinolaryngol. vol. 269. 2012. pp. 331-7. (This research paper looked at 11 adults and 8 children with TCS and found that the majority (18/19) of the patients met the diagnostic criteria for obstructive sleep apnea syndrome.)
Jones, NC, Lynn, ML, Gaudenz, K. “Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function”. Nat Med. vol. 14. 2008. pp. 125-33. (This is a mechanistic study that provides evidence that p53 inactivation can suppress craniofacial abnormalities of TCS in an animal model.)
Marres, HA, Cremers, CW, Dixon, MJ. “The Treacher Collins syndrome. A clinical, radiological, and genetic linkage study on two pedigrees”. Arch Otolaryngol Head Neck Surg. vol. 121. 1995. pp. 509-14. (This study highlights the phenotypic variability that is present in TCS.)
Marsh, JL, Celin, SE, Vannier, MW, Gado, M. “The skeletal anatomy of mandibulofacial dysostosis (Treacher Collins syndrome)”. Plast Reconstr Surg. vol. 78. 1986. pp. 460-70. (A detailed study looking at the skeletal anatomy of TCS patients of ages 1-42 years)
Narla, A, Ebert, BL. “Ribosomopathies: human disorders of ribosome dysfunction”. Blood. vol. 115. 2010. pp. 3196-205. (This is an excellent review discussing TCS and other diseases that are caused by ribosomal dysfunction.)
Posnick, JC, Ruiz, RL. “Treacher Collins syndrome: current evaluation, treatment, and future directions”. Cleft Palate Craniofac J. vol. 37. 2000. pp. 434(A comprehensive review published in 2000 that details testing and treatment for TCS)
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
- OVERVIEW: What every practitioner needs to know
- Are you sure your patient has TCS? What are the typical findings for this disease?
- What other disease/condition shares some of these symptoms?
- What caused this disease to develop at this time?
- What laboratory studies should you request to help confirm the diagnosis? How should you interpret the results?
- Would imaging studies be helpful? If so, which ones?
- Confirming the diagnosis
- If you are able to confirm that the patient has TCS, what treatment should be initiated?
- What are the possible outcomes of TCS?
- What causes this disease and how frequent is it?
- How do these pathogens/genes/exposures cause the disease?
- Other clinical manifestations that might help with diagnosis and management
- How can TCS be prevented?
- What is the evidence?